|Bid||0.00 x 10000|
|Ask||0.00 x 10000|
|Day's Range||120.64 - 123.05|
|52 Week Range||68.46 - 146.00|
|PE Ratio (TTM)||158.57|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
With a market capitalization of $35.83B, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) falls in the category of stocks popularly identified as large-caps. These are established companies that attract investors due to diversifiedRead More...
Deutsche Bank said "chances of a Vertex takeout are as good as at any point in the company's history."
CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 125,000 shares of VRTX on 12/11/2017 at an average price of $141.35 a share.
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
Galapagos stock popped Monday to Vertex's detriment after figuring out one piece of its cystic fibrosis puzzle.
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
There may be short-term volatility because of the health-care overhaul in Washington, but the long-term thesis is intact. By Phil van Doorn.